Purpose: This study was conducted to determine the feasibility of treating children in Egypt with B-cell non-Hodgkin's lymphomas according to very intensive protocols based on the German Berlin-Frankfurt-Münster (BFM) NHL 90 study. Patients and methods:From Jan 2002 through Dec 2004 thirty-four patients less than 18 years with B-cell-NHL were admitted to the department and were thus eligible for the BFM B-cell treatment. The entire group consisted of 24 males and 10 females (ratio 2.4:1). Median age was 5 years. One had stage I disease, 15 stage II, 12 stage III, and 6 stage IV lymphoma, There were 22 patients with Burkitt's lymphoma, 10 with large B-cell lymphoma, of which 2 were patients with BLL. Patients were further stratified according to clinical stage and lactate dehydrogenase (LDH) level. Therapy consisted of a perphase and short (2, 4, or courses), intensive 5-day therapy with 6 drugs.Results:The event-free survival (EFS) for the entire group was 73.5% and overall survival (OAS) was 76.4% at a median follow-up period of 24.3 months. There was a significantly better OAS for children with age between three to ten years (P=0.015), and for residents of the Cairo Metropolitan are (P=0.049). No difference was observed in the OAS based on pathological subtype, primary disease site, and gender. Stage IV and high risk group R3 patients had a marginally worse OAS (P=0.06). Patients with LDH >800 U/L had marginally worse EFS (P=0.057). Severe adverse events ≥G3 were encountered in 18.2% of treatment courses, with significantly more adverse events related to courses AA, BB, and CC ((P=0.001).Conclusion: The use of protocols based on BFM 90 study was feasible at this center. The EFS is approximately 15% lower than those reported by BFM investigations, but comparable to results from other centers.